Abstract. Receptor tyrosine kinase EphB2 and autophagic machinery are known as tumor suppressors; however, the connection remains to be elucidated. Here, we show the link between EphB2 and autophagy. Sesamin, a major lignan in sesame oil, induced autophagy in the human colon cancer cell lines HT29 and LS180, as shown by electron microscopy, as well as Western blotting and immunofluorescence imaging using an anti-LC3 antibody. Receptor tyrosine kinase array analysis revealed that sesamin treatment increased the levels of unphosphorylated -EphA1 and -EphB2 in HT29 cells. Silencing of EphA1 and EphB2 blocked sesamin-induced autophagy as well as sesamin-induced loss of cell viability. These results show that EphA1 and EphB2 play a critical role in this process. The present study reveals a novel function for EphA1 and EphB2 in the induction of autophagy, suggesting a tumor suppressor role for these proteins in colorectal cancer.
Introduction
Sesamin is a major lignan constituent of sesame oil. Sesamin isolated from the oil of sesame seeds (Sesamum indicum) has been associated with prevention of hypertension (1), thrombogenesis (2) , and hypercholesteremia by increasing hepatic fatty acid oxidation (3, 4) . In addition, sesamin exhibits antioxidative properties by reducing peroxidation products in the plasma and liver of rats. Sesamin has also been shown to have an inhibitory effect on chemically induced cancers. Sesamin inhibits the growth of a variety of neoplastic cells, including leukemia, multiple myeloma, and cancers of the colon, prostate, pancreas and lung (5, 6) . However, the mechanisms mediating the effect of sesamin on the inhibition of malignant cell growth remain to be elucidated.
Autophagy is one of the most important protein degradation systems in eukaryotic cells, and is mainly responsible for the degradation of long-lived proteins and cellular organelles (7) . There are 3 types of autophagy that differ in the mode of delivery of cargo to lysosomes, namely macroautophagy, microautophagy, and chaperone-mediated autophagy. Macroautophagy, which will be referred to as autophagy in the present study, is a bulk degradation system usually activated in response to metabolic stress, including deprivation of nutrients, oxygen, or growth factors as well as high temperature. Intracellular stresses such as damaged organelles, accumulation of mutant proteins and microbial invasion activate the autophagy pathway (8, 9) .
Dysregulation of autophagy leads to various human diseases, including neurodegenerative disorders and cancer. In general, autophagic capacity of cancer cells is lower than their normal counterpart (10) (11) (12) (13) (14) . In experimental animal model, cells from neoplastic nodules of the liver showed decreased autophagic potential than normal cells from the liver (15) (16) (17) . Beclin-1, an essential signaling molecule in the autophagy pathway, is localized to chromosome 17q21, a locus deleted in 75% of ovarian, 50% of breast, and 40% of prostate cancer (18) . Moreover, heterozygous deletion of beclin-1 in mice causes high incidences of spontaneous lung adenocarcinoma, hepatocellular carcinoma and lymphoma (19, 20) . Tumor suppressor genes that are frequently mutated in human cancers (PTEN and p53) turn autophagy on and oncogenic signals (Ras, PI3 kinase, Akt) turn it off (18, 21) . Furthermore, net deletions of several autophagyspecific genes are commonly found in human malignancies (22) . These observations indicate that autophagy is a tumor suppressor mechanism.
In the present study, we demonstrate that sesamin inhibits the growth of colon cancer cell lines by triggering autophagy and show the essential role of the ephrin receptors EphA1 and EphB2 in this process.
Materials and methods
Reagents. Sesamin was purchased from Cayman Chemical Company (Ann Arbor, MI). Anti-LC3 antibodies for immunofluorescence staining and Western blotting were purchased from MBL (Nagoya, Japan) and Cell Signaling Technology (Danvers, MA), respectively. Anti-EphB2 antibody was purchased from R&D Systems (Minneapolis, NE). Anticleaved PARP antibody was purchased from Cell Signaling Technology. Anti-HMGB1 antibody was purchased from Abcam (Cambridge, MA).
Cell culture. The human colon cancer cell lines HT29 and LS180 were obtained from American Type Culture Collection (Manassas, VA). The cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM; Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS; Hyclone Thermo Fischer Scientific, Logan, UT) in humidified 5% CO 2 at 37˚C.
Measurement of cell viability by ATP assay.
The CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI) was used according to the manufacturer's instructions. Briefly, 1,000 cells were seeded in each 96-well culture plates (Corning, Corning, NY) in 100 µl DMEM supplemented with 10% FBS. Cells were treated with various concentrations of sesamin and incubated for 72 h, after which the assay reagent was added and incubated for 10 min at room temperature (RT). The luminescent signal was measured using a Veritas Microplate Luminometer (Promega Madison, WI).
Cell cycle analysis. After the indicated treatments, the cells were collected and fixed with 70% ethanol at 4˚C. The samples were suspended in phosphate-citrate buffer. After centrifugation, the pellets were treated with RNase A, stained with propidium iodide (PI), and analyzed by flow cytometry (EPICS XL-MCL cytometer; Beckman Coulter, Fullerton, CA).
Electron microscopy. After the indicated treatments, the cells were washed and fixed with 2.5% gutaraldehyde at 4˚C until they were embedded. The samples were postfixed with 1% osmium tetroxide for 2 h at 4˚C. Cells were postfixed with 2% osmium tetroxide followed by dehydration using an increasing gradient of ethanol and propylene oxide, after which the samples were embedded in Quetol 812 (Nissin EM). Ultrathin sections were stained with uranyl acetate and lead citrate and examined with an H7500 electron microscope (Hitachi, Tokyo, Japan).
Immunofluorescent staining for LC3. After the various treatments indicated in each figure, cells were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 15 min at RT, washed, and permeabilized with 0.1% Triton X in PBS for 10 min at RT. The cells were incubated with anti-LC3 antibody (1/200 dilution) for 24 h at 4˚C, washed, and incubated with anti-rabbit IgG Alexa Flour 488 antibody (1/1,000 dilution) (Invitrogen, Carlsbad, CA) for 1 h at RT. Finally, the samples were imaged using a confocal laser scanning microscope (Radian; Carl Zeiss, Thornwood, NY).
Western blotting. Western blotting was carried out by standard methods. Briefly, cells were sonicated in lysis buffer [20 mM Tris-HCl (pH 8.0), 137 mM NaCl, 5 mM EDTA, 1% NP-40, 1 mM sodium orthovanadate, 10 µg/ml aprotinin, 10 µg/ml leupeptin] with a protease inhibitor cocktail (Sigma-Aldrich). The samples were separated on a Tris-Glycine gel (Invitrogen) under denaturing conditions. Proteins were electro-blotted onto a nitrocellulose membrane. After incubation with the indicated antibodies, the proteins were detected using ECL Western Blotting Detection kit (GE Healthcare, Piscataway, NJ). The blots were visualized using the ChemiDoc XRS system (Bio-Rad Laboratories, Hercules, CA).
Measurement of caspase-3 and -7 activities.
Caspase-3 and -7 activities were measured using Caspase-Glo 3/7 Assay (Promega). Five thousand cells were seeded in each well of 96-well plates, and the cells were treated with sesamin. The assay reagent (100 µl) was added to each well and incubated for 1 h at RT. The luminescence signal was measured using a Veritas™ Microplate Luminometer.
Measurement of early apoptosis. Apoptotic cells were analyzed using the MEBCyto-Apoptosis kit (Medical & Biological Laboratories, Nagaya, Japan), which is a combination of Annexin V and PI staining. After HT29 and LS180 cells were treated with vehicle or 50 µM sesamin for the times indicated, cells were collected, incubated in a solution containing Annexin V-FITC and PI for 15 min, and analyzed by flow cytometry.
Analysis of senescent cells. The senescence-associated β-Gal activity was measured using a senescence detection kit (Calbiochem, San Diego, CA) according to the manufacturer's instructions. Stained cells were counted using an Olympus fluorescence microscope and the percentage of positive cells are shown as bar graphs.
Receptor tyrosine kinase (RTK) array analysis. The phosphorylation status of RTKs was analyzed using a human Phospho-RTK Array (R&D Systems), which includes 42 different RTKs, following the manufacturer's instructions. Briefly, HT29 cells were treated with 50 µM sesamin or vehicle for 72 h. The samples were sonicated in lysis buffer on ice. Protein concentration was determined using the Dc Protein Assay kit (Bio-Rad Laboratories) according to the manufacturer's instructions. The array membranes were blocked and incubated with 500 µg of cell lysate overnight at 4˚C on a rocking platform shaker. Then, the array membranes were washed, incubated with HRP-conjugated anti-phosphotyrosine antibody for 2 h at RT, washed, and developed using ECL detection reagent (Amersham Pharmacia Biotec, Piscataway, NJ). The chemiluminescent signals were measured in duplicate using the ChemiDoc XRS system (Bio-Rad Laboratories), and the densitometric units were normalized against positive control spots on the same membrane provided by the manufacturer.
Transduction of short interfering RNA (siRNA). siRNAs were transfected into cells by electroporation, using Nucleofector II (Amaxa Biosystems, Gaithersburg, MD) according to the manufacturer's instructions. The programs W-017 and T-020 were used for HT29 and LS180 cells, respectively. The sequences 5'-GCAUGAACUACCUCAGUA-3' and 5'-CCAUCAAGCU CUACUGUAA-3' were used to silence EphA1 and EphB2, respectively. The sequence 5'-UAGCGACUAAACACAUCA AUU-3' was used as a non-silencing control. These siRNAs were synthesized and purchased from Sigma-Aldrich Japan (Ishikari, Japan).
Quantification of EphA1 and EphB2 mRNA. The expression of EphA1 and EphB2 mRNA was determined by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) using ABI PRISM 7700 sequence detector system (Applied Biosystems, Foster City, CA). Total RNA was isolated using the RNeasy Plus Mini kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. The cDNA was reverse transcribed using Taqman Reverse Transcription Reagents (Applied Biosystems, Branchburg, NJ). The gene-specific primers and fluorescent hybridization probes were as follows. For EphA1 mRNA, 5'-AACCTGCCAGACTAGGCTATCG-3', 5'-ACCC CCACCTCCCTTTTAAA-3' and 5'-(FAM) TGCTCTGCAC CCCAGAAAACCTCTTTG (TAMRA)-3', were used as forward primer, reverse primer, and the TaqMan probe, respectively. For EphB2, 5'-AGACCATGACAGAAGCCGAG TAC-3' , 5'-CAACCACAGCAATGAGGAAGAC-3' and 5'-(FAM) AAGCATCCAGGAGAAGTTGCCACTCATC (TAMRA)-3' were used as forward primer, reverse primer, and the TaqMan probe, respectively. The amounts of mRNA were normalized to the ratios of GAPDH. PCR primers and the probe for GAPDH were purchased from Applied Biosystems.
Results

Sesamin reduces cell viability in colon cancer cell lines.
To examine the antitumor effect of sesamin in colon cancer cells, HT29 and LS180 cells were treated with various concentrations of sesamin up to 72 h. As shown in Fig. 1A , sesamin inhibited cell viability in a dose-and time-dependent manner. A longterm assay also showed growth inhibition of cells treated with sesamin (Fig. 1B) . Further investigation into the mechanism of sesamin-mediated inhibition of cell growth showed that sesamin had no apparent effect on cell cycle (Fig. 1C) .
Sesamin induces autophagy in colon cancer cells. To further investigate the mecahism how sesamin reduces cell viability of colon cancer cells, electron-microscopy studies were carried out, and the results showed prominent double-membrane vacuoles engulfing cytosolic components in sesamin-treated cells ( Fig. 2A) . Cells showing the characteristic signs of necrosis or apoptosis were not detected. As shown in Fig. 2B , in cells treated with vehicle, LC-3 was distributed in the cytosol, while sesamin treatment resulted in the detection of LC3 punctate structures. The results of the Western blot analysis using an anti-LC3 antibody were consistent with the immunofluorescence study and showed that sesamin treatment induced LC3-II conversion in a time-dependent manner ( Fig. 2C and D) . Because monodansylcadaverine (MDC) accumulates in mature autophagic vacuoles, MDC staining can be used to detect the presence of these vacuoles (23) . As shown in Fig. 2E , sesamin treatment caused an increase MDC-positive cells.
Sesamin treatment did not induce apoptosis, as seen in the absence of PARP cleavage by Western blotting (Fig. 3A) , the measurement of caspase-3/7 activity (Fig. 3B) , and negative Annexin V staining (Fig. 3C) . Detection of high mobility group box 1 (HMGB1) by immunofluorescence and β-galactosidase activity assay did not show the presence of necrosis or cellular senescence, respectively ( Fig. 3D and E) . These results indicate that sesamin-induced loss of cell viability is associated with autophagy in colon cancer cells. Sesamin reduces phosphorylation of ephrin receptors. Based on a report that the lignan picropodophyllin (PPP) inhibits tyrosine phosphorylation of insulin-like growth factor-1 receptor (IGF1-R) (24) , and on the fact that the downstream effector of the Akt/ mammalian target of rapamycin (mTOR) pathway is a regulator of autophagy, the possible effect of sesamin on inhibition of the tyrosine phosphorylation of one of the RTKs was examined. Among 42 RTKs examined, EphA1 and EphB2 showed a decrease in tyrosine phosphorylation after sesamin treatment, with EphB2 showing greater decrease (Fig. 4A and B) . Most of the other receptors evaluated showed minimal changes, or an increase in phosphorylation status, including IGF1-R (Fig. 4C) .
Silencing of EphA1 and EphB2 inhibits autophagy.
To confirm that EphA1 and EphB2 play an essential role in the induction of autophagy, siRNA-mediated silencing of EphA1 and EphB2 was performed followed by treatment of cells with sesamin. siRNA against EphA1 or EphB2 effectively silenced the mRNA expression of these molecules (Fig. 5A) . In HT29 cells, silencing of EphA1 or EphB2 was not sufficient to inhibit sesamininduced autophagy (Fig. 5B) . In LS180 cells, silencing of EphB2 abrogated the induction of autophagy. As the RTK array showed reduced phosphorylation of both EphA1 and EphB2, we silenced EphA1 and EphB2 in HT29 cells simultaneously. As shown in the Fig. 5B (right panels) , simultaneous silencing of EphA1 and EphB2 blocked the induction of autophagy, which was confirmed by Western blotting against LC3. The effect of EphA1 and EphB2 silencing on autophagy inhibition was also confirmed by immunofluorescence using an anti-LC3 antibody (Fig. 5C) . These results show that EphA1 and EphB2 play an essential role in sesamin-induced autophagy. 
Discussion
The present study demonstrated that sesamin inhibits cell viability of colon cancer cell lines through a mechanism involving autophagy. In addition, EphA1 and EphB2 play an essential role in the induction of autophagy.
Prior reports suggested that sesamin may inhibit the growth of cancer cells by down-regulating the NF-κB pathway (5), P-glycoprotein (25) , or cyclin D1 (26) . The induction of autophagy, found in the present study, is a novel mechanism of sesamininduced inhibition of cancer cell growth.
The finding that sesamin induces autophagy via EphA1 and EphB2 is intriguing because autophagy and EphB2 are considered as tumor suppressors (18) . Eph receptors constitute the largest subgroup of RTKs (27) . EphB2 is a unique receptor in RTK family because of its tumor suppressor functions. EphB2 maps at chromosome 1p36.1, which is frequently deleted in colorectal cancer (28) . EphB2 is frequently mutated in colorectal cancer (29) ; EphB2 receptor variants are reported in the probands of familial colorectal cancer (30) . Expression level of EphB2 decreases with the progress of colorectal lesions in dysplasia-adenoma-carcinoma sequence (31) and the level of EphB2 inversely correlates with prognosis of patients with colorectal cancer (32, 33) . Furthermore, reduction of EphB2 function accelerates tumourigenesis in the colon and rectum of Apc Min/+ mice (31). According to previous reports, the best-characterized functions of ephrin-Eph interactions in the intestinal system are the regulation of cell positioning, cell migration and progenitor cell proliferation (34) (35) (36) . Among these functions, the compartmentalization of tumor cells is thought to be a tumor suppressor function of EphB2 (36) . In the present study, silencing of EphB2 abrogated autophagy induced by sesamin, suggesting that the induction of autophagy may be another tumor suppressor mechanism of EphB2. As EphA1 is 53% identical to EphB2 in the cytoplasmic domain, EphA1 may share functions of EphB2 in the autophagic process.
The effect of autophagy in favoring or interfering with cancer therapeutics is a matter of controversy (37, 38) . Many anticancer drugs including rapamycin, tamoxifen, and HDAC inhibitors induce autophagy-associated cell death in cancer cells. On the other hand, inhibition of autophagy enhances the effect of cancer therapeutics in many types of malignancies, including colon cancer (39) . The present study showed that autophagy induced by sesamin is reducing cell viability of colon cancer cells, at least in vitro. It is still an open question whether autophagy induction by EphB2, and possibly by EphA1, is beneficial or harmful for cancer cells in vivo.
The present result of the RTK array analysis, identifying EphA1 and EphB2 as the only receptors showing reduced phosphorylation levels in sesamin treated cells, is intresting.
Phosphorylation of RTKs indicates activation of the receptors and the downstream Akt pathway, which leads to inhibition of autophagy. However, sesamin-treated cells showed an autophagic phenotype with decreased cell proliferation in vitro. This observation suggests that unphosphorylated EphA1 and EphB2 may overwhelm the signals from the other activated RTKs.
In conclusion, we found that EphA1 and EphB2 acts as regulators of autophagy induced by sesamin. This study provides a novel molecular mechanism for the autophagic process as well as a basis for targeting EphA1 and EphB2 in the chemoprevention of colorectal cancer. . Silencing of EphA1 and EphB2 counteracts sesamin-induced loss of cell viability. Non-silencing control siRNAs, siRNAs against EphA1 and/ or EphB2 were transduced into HT29 cells. Then, the transfectants were treated with different concentrations of sesamin indicated in the figure for 48 h and the cell viability was measured as described in Materials and methods. * p<0.001 compared to the value of non-silencing control.
